Company: STAA
Filing Date: 2025-10-30
Form Type: DEFA14A
Source: 0001193125-25-258558
Chunk: 10

Company: STAAR SURGICAL CO
Filing Date: 2025-10-30
Form: DEFA14A
Chunk 10
---
 INCORPORATED 501 Madison Avenue, 20th Floor New York, New York 10022 Stockholders, please call toll-free: (877) 750-8233 Banks and brokerage firms, please call: (212) 750-5833 (2) Supplements to “Special Note Regarding Forward-Looking Statements” The section titled “Special Note Regarding Forward-Looking Statements” beginning on page 21 of the proxy statement is hereby amended and supplemented as follows: The information covered by this proxy statement , as supplemented from time to time, including on October 14, 2025 and October 30, 2025, may contain forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended (which this proxy statement refers to as the “Securities Act”), and Section 21E of the Exchange Act, as amended by the Private Securities Litigation Reform Act of 1995, such as statements about the consummation of the proposed Merger and the anticipated benefits thereof. Forward-looking statements often contain words such as “anticipate,” “believe,” “expect,” “plan,” “estimate,” “project,” “continue,” “will,” “should,” “may” and similar terms. These forward-looking statements do not constitute guarantees of future performance and are subject to a variety of risks and uncertainties that may cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. In addition, STAAR has based some of these forward-looking statements on assumptions about future events that may prove to be inaccurate. Such factors, risks and uncertainties include:

| • |     | the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger            
 Agreement between the parties to the Merger or extend the anticipated timetable for completion of the proposed transaction; |

7

| • |     | the failure to obtain the Stockholder Approval, the likelihood of which is increased if there is no                                      
 amendment or modification to the existing terms of the Merger Agreement, and the outcome of the Broadwood Group’s ongoing proxy contest; |

| • |     | the failure to obtain certain required regulatory approvals or the failure to satisfy any of the other closing 
 conditions to the completion of the Merger within the expected timeframes or at all;                           |

| • |     | risks related to disruption of management’s attention from STAAR’s ongoing business operations due to                                                                                              
 the Merger and efforts by the Broadwood Group